Hostname: page-component-848d4c4894-v5vhk Total loading time: 0 Render date: 2024-06-16T14:40:37.415Z Has data issue: false hasContentIssue false

Estimating coronavirus disease 2019 (COVID-19)–caused deaths in hospitals and healthcare units: Do hospital-acquired infections play a role? Comments with a proposal

Published online by Cambridge University Press:  19 March 2021

Salvatore Chirumbolo*
Affiliation:
Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
Vincenzo Simonetti
Affiliation:
Oxygen-Ozone Therapy Scientific Society (SIOOT), Gorle, Italy
Marianno Franzini
Affiliation:
SIOOT, High School in Oxygen Ozone Therapy, University of Pavia, Italy SIOOT International, Community Clinic, Gorle Bergamo, Italy
Luigi Valdenassi
Affiliation:
SIOOT, High School in Oxygen Ozone Therapy, University of Pavia, Italy SIOOT International, Community Clinic, Gorle Bergamo, Italy
Dario Bertossi
Affiliation:
Department of Surgery, Dentistry, Pediatrics and Gynecology Unit of Maxillo-Facial Surgery, University of Verona, Verona, Italy
Sergio Pandolfi
Affiliation:
SIOOT, High School in Oxygen Ozone Therapy, University of Pavia, Italy SIOOT International, Community Clinic, Gorle Bergamo, Italy
*
Author for correspondence: Prof Salvatore Chirumbolo, E-mail: salvatore.chirumbolo@univr.it
Rights & Permissions [Opens in a new window]

Abstract

Type
Letter to the Editor
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

To the Editor—A recent paper by Giacobbe et al Reference Giacobbe, Battaglini and Enrile1 reported that 171 of 586 patients (29%) (mean age, 64 years) hospitalized for coronavirus disease 2019 (COVID-19) in intensive care units (ICUs) of major Italian hospitals also had ventilator-associated pneumonia (VAP) caused by superinfection, mainly with Pseudomonas aeruginosa (35%) and Staphylococcus aureus (23%). These authors reported that the 30-day case fatality caused by VAP was 46% (77 of 171). Furthermore, in multivariate analysis, the odds ratio (OR) of septic shock on VAP onset was 3.30 (95% CI, 1.43–7.61; P = .005) and the OR of acute respiratory distress syndrome (ARDS) was 13.21 (95% CI, 3.05–57.26; P < .001). Both were associated with mortality. Reference Giacobbe, Battaglini and Enrile1 These authors collected bronchoalveolar lavage fluid (BALF) from 79 of 171 patients and reported positive microbial cultures in 77 of 79 BALFs (97%). Reference Giacobbe, Battaglini and Enrile1

Hospital-acquired infections (HAIs) are a huge concern for hospitals in Italy. A survey by Lizioli et al Reference Lizioli, Privitera and Alliata2 revealed that most HAIs in Lombardy, the Italian region with the most COVID-19 deaths, occurred in ICUs. The high prevalence of HAIs in ICUs in Italy has also been reported by other authors Reference Nicastri, Petrosillo and Martini3,Reference Zotti, Messori Ioli and Charrier4 who associated such infections with the use of urinary catheter, surgical drainage, and intravascular catheters, as well as mechanical ventilation. Reference Zotti, Messori Ioli and Charrier4

A major COVID-19 concern has been widely associated with activity in ICUs. Lockdown policy and restrictions in social habits have been implemented to decrease the burden of hospitalized people in ICUs. However, despite several reports in the literature, Reference Bardi, Pintado and Gomez-Rojo5,Reference Maes, Higginson and Pereira-Dias6 a sound public debate about HAIs, particularly among elderly people with severe comorbidities, has not been addressed by politicians or journalists in Italy. Furthermore, neither a proper democratic debate nor a political discussion has included more suitable and effective protocols aimed toward greatly reducing the impact of HAIs in ICUs among COVID-19 patients. Thus far, the public debate has included issues regarding social contacts and severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in the general population, but HAIs have not been adequately considered. Undoubtedly, the dramatic increase in COVID-19 deaths includes HAI coinfection cases. We aimed to calculate a more correct estimation of these cases using data from Italian Ministry of Health that were publicly available online on February 14, 2021. Among the entire COVID-19–positive population (2,721,879 people), 2,085 patients went to an ICU and 382,249 did not need hospitalization (good outcome–group 1); 93,577 patients died and 2,275,519 individuals were discharged or healed from the infection (good outcome–group 2). The relative risk (RR) of dying in an ICU from COVID-19 was 7.28, with an OR of 7.54 (95% confidence interval [CI], 7.22–7.87). However, the RR of dying from an HAI coinfection was 24.59, and the rate of VAP-associated death may be as low as 13.34% Reference Giacobbe, Battaglini and Enrile1 with an OR of 28.22 (95% CI, 26.93–29.58). HAIs represent a 4-fold RR of dying during a COVID-19 ICU hospitalization compared to COVID-19 patients who recover, are discharged, or reach RT-PCR swab negativity, which account for at least 81.76% of all COVID-19 patients.

A very recent report showed that gram-negative bacteria, more than SARS-CoV-2, are detectable in ICUs, particularly in sinks and siphons, compared to the absence of SARS-CoV-2 on surfaces and instruments in the ICU environment. Reference Hofmaenner, Wendel Garcia and Duvnjak7 This finding suggests that a correct sanitization protocol is particularly crucial. Ozone, for example, can dampen completely gram-negative bacteria, such as P. aeruginosa, to an extent comparable to chlorhexidine. Reference Oliver, Bredarioli, Leandro, Ferreira, Veiga and Dias8 Notably, Hanifi et al Reference Hanifi, Masoumi, Reza Jamshidi and Faghihzadeh9 reported the ability of ozonated water and chlorhexidine gluconate to reduce VAP. This report assessed further evidence showing the ability of gaseous ozone and ozonized water to completely remove SARS-CoV-2 contamination from any surface. Reference Murata, Komoto and Iwahori10 These authors addressed oral care with ozonated water in 39 patients and with chlorhexidine gluconate in 35 patients to reduce VAP incidence. Patients were 67.57% men and 32.43% women, aged between 18 and 68 years, and ∼63.51% were admitted to ICUs. These authors concluded that ozone was more effective in reducing VAP than chlorhexidine. Reference Hanifi, Masoumi, Reza Jamshidi and Faghihzadeh9 Usual detergents and disinfectants can reduce P. aeruginosa on surfaces from 1.17 to 1.63 log (ie, from 92.93% to 97.31% CFU/cm2), whereas ozone reduced bacterial biofilms to 7.34 log (99.99999% CFU/cm2). Reference Oliver, Bredarioli, Leandro, Ferreira, Veiga and Dias8 Ozone, in particular, enables complete environmental clearance of SARS-CoV2 viral particles. A plaque test of VERO-E6/TMPRSS2 cells infected with SARS-CoV2, performed by Yano et al, Reference Yano, Nakano, Suzuki, Nakano, Kasahara and Hosoi11 calculated that 1.0 ppm ozone treatment for 60 minutes reduced the viral presence in the cell lines from 1.7×107 PFU/mL to 1.7×104 PFU/mL, whereas controls were reduced to 5.8×105 PFU/mL. With 6 ppm ozone for 55 minutes, the reduction reached 1.0×103 PFU/mL and only 2.0×106 for the control. Reference Yano, Nakano, Suzuki, Nakano, Kasahara and Hosoi11

A correct policy of sanitization in ICUs is mandatory to reduce deaths in these areas and to shift the awkward burden of lockdown to an improved policy of hospital service and healthcare management supported by physicians and care givers. The impact of HAIs can be easily dampened by widespread use of ozone in ICUs, a product that usually degrades into molecular oxygen and has low toxicity compared to other sanitization products. To significantly reduce deaths from COVID-19, political discourse must give attention to the urgent breakdowns that result in HAIs in hospitals and ICUs concurrent with COVID-19.

Acknowledgments

A special thank to the SIOOT organizing Committee.

Financial support

No financial support was provided relevant to this article.

Conflicts of interest

All authors report no conflicts of interest relevant to this article.

References

Giacobbe, DR, Battaglini, D, Enrile, EM, et al. Incidence and prognosis of ventilator-associated pneumonia in critically ill patients with COVID-19: a multicenter study. J Clin Med 2021;10:555.CrossRefGoogle ScholarPubMed
Lizioli, A, Privitera, G, Alliata, E, et al. Prevalence of nosocomial infections in Italy: result from the Lombardy survey in 2000. J Hosp Infect 2003;54:141148.CrossRefGoogle ScholarPubMed
Nicastri, E, Petrosillo, N, Martini, L, et al. Prevalence of nosocomial infections in 15 Italian hospitals: first point prevalence study for the INF-NOS project. Infection 2003;31 suppl 2:1015.Google Scholar
Zotti, CM, Messori Ioli, G, Charrier, L, et al. Hospital-acquired infections in Italy: a region wide prevalence study. J Hosp Infect 2004;56:142149.CrossRefGoogle ScholarPubMed
Bardi, T, Pintado, V, Gomez-Rojo, M, et al. Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. Eur J Clin Microbiol Infect Dis 2021;40:495502.Google ScholarPubMed
Maes, M, Higginson, E, Pereira-Dias, J, et al. Ventilator-associated pneumonia in critically ill patients with COVID-19. Crit Care 2021;25:25.CrossRefGoogle ScholarPubMed
Hofmaenner, DA, Wendel Garcia, PD, Duvnjak, B, et al. Bacterial but no SARS-CoV-2 contamination after terminal disinfection of tertiary-care intensive care units treating COVID-19 patients. Antimicrob Resist Infect Control 2021;10:11.CrossRefGoogle Scholar
Oliver, JC, Bredarioli, PAP, Leandro, FD, Ferreira, CBRJ, Veiga, SMOM, Dias, ALT. Ozone against Pseudomonas aeruginosa biofilms in contact lenses storage cases. Rev Inst Med Trop Sao Paulo 2019;61:e23.CrossRefGoogle ScholarPubMed
Hanifi, N, Masoumi, M, Reza Jamshidi, M, Faghihzadeh, S. The effect of ozonated water and chlorehixidine gluconate on prevention of ventilator-associated pneumonia: a double blind, randomized, clinical trial Iran Red Crescent Med J 2107;19:e60576.Google Scholar
Murata, T, Komoto, S, Iwahori, S, et al. Reduction of severe acute respiratory syndrome coronavirus-2 infectivity by admissible concentration of ozone gas and water. Microbiol Immunol 2020. doi: 10.1111/1348-0421.12861.CrossRefGoogle Scholar
Yano, H, Nakano, R, Suzuki, Y, Nakano, A, Kasahara, K, Hosoi, H. Inactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by gaseous ozone treatment. J Hosp Infect 2020;106:837838.CrossRefGoogle Scholar